Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia

Leuk Res. 2012 Apr;36(4):474-8. doi: 10.1016/j.leukres.2011.10.015. Epub 2011 Nov 8.

Abstract

Therapy-related acute promyelocytic leukemia (t-APL) has been reported as a late complication of exposure to radiotherapy and/or chemotherapeutic agents targeting DNA topoisomerase II. We have analyzed in t-APL novel gene mutations recently associated with myeloid disorders. Unlike previous reports in acute myeloid leukemia (AML), our results showed neither IDHs nor TET2 mutations in t-APL. However we found an R882H mutation in the DNMT3A gene in a patient with t-APL suggesting a possible role of this alteration in the pathogenesis of t-APL.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Child
  • DNA (Cytosine-5-)-Methyltransferases / genetics
  • DNA Methyltransferase 3A
  • DNA Mutational Analysis
  • DNA-Binding Proteins / genetics
  • Dioxygenases
  • Female
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Leukemia, Promyelocytic, Acute / etiology*
  • Leukemia, Promyelocytic, Acute / genetics*
  • Male
  • Middle Aged
  • Proto-Oncogene Proteins / genetics
  • Radiotherapy / adverse effects
  • Young Adult
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Antineoplastic Agents
  • DNA-Binding Proteins
  • DNMT3A protein, human
  • Proto-Oncogene Proteins
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • Dioxygenases
  • TET2 protein, human
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3